817 related articles for article (PubMed ID: 25960634)
1. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
2. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
3. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
4. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study.
Liu K; Song Y; Xu G; Ye J; Wu Z; Liu X; Dong X; Zhang M; Xing Y; Zhu S; Chen X; Shen Y; Huang H; Yu L; Ke Z; Rosenfeld PJ; Kaiser PK; Ying G; Sun X; Xu X;
Am J Ophthalmol; 2019 Jan; 197():156-167. PubMed ID: 30148987
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
Li X; Xu G; Wang Y; Xu X; Liu X; Tang S; Zhang F; Zhang J; Tang L; Wu Q; Luo D; Ke X;
Ophthalmology; 2014 Sep; 121(9):1740-7. PubMed ID: 24793528
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept for the treatment of neovascular age-related macular degeneration.
Verner-Cole EA; Davis SJ; Lauer AK
Drugs Today (Barc); 2012 May; 48(5):317-29. PubMed ID: 22645720
[TBL] [Abstract][Full Text] [Related]
7. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
Dixon JA; Oliver SC; Olson JL; Mandava N
Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
[TBL] [Abstract][Full Text] [Related]
8. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
9. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Yang S; Zhao J; Sun X
Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
[TBL] [Abstract][Full Text] [Related]
10. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
[TBL] [Abstract][Full Text] [Related]
11. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration].
Budzinskaya MV; Plyukhova AA; Sorokin PA
Vestn Oftalmol; 2017; 133(4):103-108. PubMed ID: 28980574
[TBL] [Abstract][Full Text] [Related]
12. An update on conbercept to treat wet age-related macular degeneration.
Ferro Desideri L; Traverso CE; Nicolò M
Drugs Today (Barc); 2020 May; 56(5):311-320. PubMed ID: 32406878
[TBL] [Abstract][Full Text] [Related]
13. Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration.
Falavarjani KG; Sadda SR
Curr Pharm Des; 2017; 23(4):535-541. PubMed ID: 27981904
[TBL] [Abstract][Full Text] [Related]
14. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
15. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis.
Cui C; Lu H
Clin Interv Aging; 2018; 13():51-62. PubMed ID: 29343949
[TBL] [Abstract][Full Text] [Related]
16. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.
Teo KYC; Gillies M; Fraser-Bell S
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X
Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study.
Jing J; Yinchen S; Xia C; Jing W; Chong C; Xun X; Hengye H; Kun L
BMC Ophthalmol; 2018 Jul; 18(1):181. PubMed ID: 30041608
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
20. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]